Semaglutide Side Effects & Management Strategies

Side Effect Overview

Like all medications, semaglutide can cause side effects. Most are gastrointestinal in nature, tend to be mild to moderate, and typically improve as the body adjusts during the dose-escalation period. Understanding what to expect helps patients manage symptoms effectively and know when to seek medical attention.

Key takeaway: The gradual titration schedule (starting at 0.25mg and increasing over 16 weeks) is specifically designed to minimise side effects. Most patients find that symptoms diminish significantly after the first few weeks at each dose level.

Common Side Effects

The following side effects affect more than 5% of patients in clinical studies. They are generally most pronounced during dose-escalation phases and tend to decrease over time.

Side Effect	Frequency	Management Strategy
Nausea	~44%	Eat smaller meals, avoid fatty/greasy foods, stay hydrated, eat bland foods when symptomatic
Diarrhoea	~30%	Increase water intake, avoid high-fibre foods temporarily, consider electrolyte replacement
Vomiting	substantial	Eat slowly, avoid lying down after meals, sip ginger tea, take small sips of clear fluids
Constipation	substantial	Increase dietary fibre gradually, drink adequate water, gentle physical activity
Abdominal pain	~20%	Eat smaller portions, avoid trigger foods, mild discomfort usually resolves within days
Headache	~14%	Stay hydrated, maintain regular meals, over-the-counter pain relief if needed
Fatigue	~11%	Ensure adequate caloric intake (do not undereat), maintain sleep hygiene, light exercise
Injection site reactions	~6%	Rotate injection sites, allow medication to reach room temperature before injecting

Practical Management Tips

Managing Nausea (Most Common)

Eat 5-6 small meals instead of 2-3 large ones
Stop eating when you feel full -- do not push through
Avoid high-fat, greasy, fried, or spicy foods
Ginger (tea, chews, supplements) can help reduce nausea
Eat bland foods (rice, toast, bananas) when symptomatic

Preventing Dehydration

Aim for 2-3 litres of water daily (especially important in Nigerian heat)
If experiencing diarrhoea or vomiting, add oral rehydration salts (ORS)
Sip fluids throughout the day rather than large amounts at once
Monitor urine colour -- pale yellow indicates adequate hydration
Coconut water is an excellent natural electrolyte source available in Nigeria

Serious Side Effects (Seek Immediate Medical Attention)

While rare, some side effects of semaglutide require urgent medical attention. Contact your healthcare provider immediately or go to the nearest emergency department if you experience any of the following:

Pancreatitis

Severe, persistent abdominal pain that may radiate to the back, with or without vomiting. Pancreatitis has been reported in patients taking GLP-1 receptor agonists. If suspected, semaglutide should be discontinued.

Signs: Severe upper abdominal pain, nausea/vomiting, tenderness to touch

Gallbladder Problems

Rapid weight loss can increase the risk of gallstones (cholelithiasis). Semaglutide may also independently increase gallbladder-related events.

Signs: Sudden, intense right upper abdominal pain, pain between shoulder blades, nausea, vomiting, fever

Thyroid Tumours (Precautionary)

In animal studies, semaglutide caused thyroid C-cell tumours, including medullary thyroid carcinoma (MTC). It is unknown whether semaglutide causes thyroid C-cell tumours in humans. This is a precautionary warning.

Signs: Lump or swelling in neck, hoarseness, difficulty swallowing, shortness of breath

Severe Allergic Reaction

Anaphylaxis and serious allergic reactions have been reported rarely. Discontinue semaglutide immediately and seek emergency care.

Signs: Swelling of face/lips/tongue/throat, difficulty breathing, severe rash, rapid heartbeat, dizziness

Kidney Problems

Dehydration from severe gastrointestinal side effects (vomiting, diarrhoea) can worsen kidney function, particularly in patients with pre-existing kidney disease.

Signs: Decreased urination, swelling in legs/feet, persistent nausea/vomiting, confusion

Contraindications

Semaglutide should NOT be used by patients with the following conditions. Your doctor will screen for these during the initial consultation.

Contraindication	Reason
Medullary thyroid carcinoma (MTC) history	Personal or family history of MTC. Animal studies showed thyroid C-cell tumour risk.
MEN2 syndrome	Multiple Endocrine Neoplasia syndrome type 2 increases MTC risk.
Pregnancy or planning pregnancy	Animal studies suggest potential fetal harm. Discontinue at least 2 months before planned conception.
Breastfeeding	Unknown whether semaglutide passes into breast milk.
Known hypersensitivity	Prior allergic reaction to semaglutide or any component of the formulation.
History of pancreatitis	Use with caution; GLP-1 agonists may increase pancreatitis risk.

When to Contact Your Doctor

Contact Within 24 Hours

Persistent nausea/vomiting lasting more than 3 days
Unable to keep food or fluids down for 24+ hours
Signs of dehydration (dark urine, dizziness, dry mouth)
New or worsening constipation not responding to management
Unusual fatigue or weakness
Injection site reactions that worsen or don't resolve

Seek Emergency Care Immediately

Severe, persistent abdominal pain (possible pancreatitis)
Signs of allergic reaction (swelling, breathing difficulty)
Lump or swelling in neck (thyroid concern)
Symptoms of severe hypoglycaemia (confusion, seizure, loss of consciousness)
Vision changes (especially in diabetic patients)
Signs of kidney failure (very low urine output, severe swelling)

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Revised 2024.
Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. PMID: 37796527
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12:645563. PMID: 34305810
Bjerre Knudsen L, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486. PMID: 20203154
Faillie JL, et al. GLP-1 Receptor Agonists and the Risk of Pancreatitis. Diabetes Metab. 2022;48(1):101283. PMID: 34509611
Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes. Lancet. 2021;397(10278):971-984. PMID: 33667417
Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy. JAMA. 2021;325(14):1403-1413. PMID: 33625476
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425. PMID: 33755728
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131

Medical Review

This article was reviewed by the Semaglutide.ng team for clinical accuracy. Content is based on published prescribing information, FDA safety communications, and peer-reviewed research. It does not constitute medical advice. Always consult a qualified healthcare provider regarding side effects.

Last reviewed: February 2026

Semaglutide Side Effects